Zacks Investment Research Upgrades United Therapeutics Corporation (UTHR) to “Hold”

United Therapeutics Corporation (NASDAQ:UTHR) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Also, recently, the company announced that regulatory issues will delay the U.S. launch of RemoSynch. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Though Orenitram sales growth was slow in 2016, management estimates the drug to have $1 billion peak revenue potential. Shares also underperformed the industry this year so far. Estimates have remained stable ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters.”

UTHR has been the subject of several other research reports. BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. ValuEngine downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 8th. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research note on Friday, July 14th. UBS AG reiterated a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. Five research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation has a consensus rating of “Hold” and a consensus target price of $132.09.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 1.85% during midday trading on Monday, hitting $121.58. The company had a trading volume of 97,505 shares. The company’s 50 day moving average is $124.46 and its 200 day moving average is $126.92. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The firm has a market cap of $5.28 billion, a price-to-earnings ratio of 14.10 and a beta of 1.50.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $4.42 EPS. Equities analysts forecast that United Therapeutics Corporation will post $10.60 earnings per share for the current fiscal year.

WARNING: “Zacks Investment Research Upgrades United Therapeutics Corporation (UTHR) to “Hold”” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/09/zacks-investment-research-upgrades-united-therapeutics-corporation-uthr-to-hold.html.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total value of $164,250.24. Following the completion of the transaction, the chief executive officer now owns 2,301 shares of the company’s stock, valued at approximately $306,769.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 580 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the transaction, the director now directly owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The disclosure for this sale can be found here. Insiders have sold a total of 18,298 shares of company stock valued at $2,322,339 in the last three months. 7.80% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Eagle Global Advisors LLC acquired a new position in United Therapeutics Corporation in the 2nd quarter valued at approximately $206,000. Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation in the 1st quarter valued at approximately $230,000. TLP Group LLC acquired a new position in United Therapeutics Corporation in the 2nd quarter valued at approximately $246,000. HPM Partners LLC raised its holdings in United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 15 shares in the last quarter. Finally, Fort L.P. raised its holdings in United Therapeutics Corporation by 5.2% in the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 99 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of

According to Zacks, “United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Also, recently, the company announced that regulatory issues will delay the U.S. launch of RemoSynch. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Though Orenitram sales growth was slow in 2016, management estimates the drug to have $1 billion peak revenue potential. Shares also underperformed the industry this year so far. Estimates have remained stable ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters.”

UTHR has been the subject of several other research reports. BidaskClub upgraded United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. ValuEngine downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Friday, September 8th. Jefferies Group LLC reiterated a “sell” rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research note on Friday, July 14th. UBS AG reiterated a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. Five research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation has a consensus rating of “Hold” and a consensus target price of $132.09.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded down 1.85% during midday trading on Monday, hitting $121.58. The company had a trading volume of 97,505 shares. The company’s 50 day moving average is $124.46 and its 200 day moving average is $126.92. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89. The firm has a market cap of $5.28 billion, a price-to-earnings ratio of 14.10 and a beta of 1.50.

United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $4.42 EPS. Equities analysts forecast that United Therapeutics Corporation will post $10.60 earnings per share for the current fiscal year.

WARNING: “Zacks Investment Research Upgrades United Therapeutics Corporation (UTHR) to “Hold”” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://ledgergazette.com/2017/10/09/zacks-investment-research-upgrades-united-therapeutics-corporation-uthr-to-hold.html.

In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 1,232 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $133.32, for a total value of $164,250.24. Following the completion of the transaction, the chief executive officer now owns 2,301 shares of the company’s stock, valued at approximately $306,769.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Christopher Causey sold 580 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the transaction, the director now directly owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The disclosure for this sale can be found here. Insiders have sold a total of 18,298 shares of company stock valued at $2,322,339 in the last three months. 7.80% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the business. Eagle Global Advisors LLC acquired a new position in United Therapeutics Corporation in the 2nd quarter valued at approximately $206,000. Clarity Capital KCPS Ltd. acquired a new position in United Therapeutics Corporation in the 1st quarter valued at approximately $230,000. TLP Group LLC acquired a new position in United Therapeutics Corporation in the 2nd quarter valued at approximately $246,000. HPM Partners LLC raised its holdings in United Therapeutics Corporation by 0.8% in the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 15 shares in the last quarter. Finally, Fort L.P. raised its holdings in United Therapeutics Corporation by 5.2% in the 2nd quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after acquiring an additional 99 shares in the last quarter.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply